tbuckley/cabot-search huggingface dataset:
Leaders in cardiovascular research: Eugene Braunwald
Authors: Eugene Braunwald, Tomasz J Guzik
Journal: Cardiovascular Research (2022)

Q: What is the secret of success in science and medicine-is it ambition or talent?I think that both are important.But luck or serendipity also plays an important role.It's being in the right place, at the right time, with the right people.I have been very fortunate that I was lucky three times in my training.In 1951, my medical school was one of the only schools that provided research experience for interested students.I entered a cardiac catheterization laboratory studying the hemodynamic characteristics of heart failure, a subject I have continued to work on for 70 years.Because of that experience as a student, 3 years later I was accepted for a research fellowship in the laboratory of André Cournand, who received a Nobel Prize for his pioneering studies on cardiac catheterization.After I finished
TIME SINCE LAST CHEMOTHERAPY AND COVID-19 OUTCOMES IN CARDIO-ONCOLOGY INPATIENTS
Authors: Aayush Visaria, Stephanie Hong, Sijin Wen, Priyal Makwana, Scott Chapman, Maryam Khodaverdi, Jasvinder Singh, Oluwabunmi Ogungbe, Jacob Neumann, George G. Sokos, Brijesh D. Patel
Journal: Journal of the American College of Cardiology (2022)
A Comparison of International League of Associations for Rheumatology and Pediatric Rheumatology International Trials Organization Classification Systems for Juvenile Idiopathic Arthritis Among Children in a Canadian Arthritis Cohort
Authors: Jennifer J. Y. Lee, Simon W. M. Eng, Jaime Guzman, Ciáran M. Duffy, Lori B. Tucker, Kiem Oen, Rae S. M. Yeung, Brian M. Feldman
Journal: Arthritis & Rheumatology (2022)

Objective The aim of the Paediatric Rheumatology International Trials Organisation (PRINTO) juvenile idiopathic arthritis (JIA) classification criteria, which is still in development, is to identify homogeneous groups of JIA patients. This study was undertaken to compare International League of Associations for Rheumatology (ILAR) JIA classification criteria and PRINTO JIA classification criteria using data from the ReACCh‐Out (Research in Arthritis in Canadian Children, Emphasizing Outcomes) cohort. Methods We used clinicobiologic data recorded within 7 months of diagnosis to assign a diagnosis of JIA and identify subcategories of JIA among 1,228 patients according to the 2 JIA classification systems. We compared the proportions of patients classified and the alignment of classification categories with clinicobiologic subtypes and adult arthritis types. Results The PRINTO criteria classified 244 patients (19.9%) as having early‐onset antinuclear antibody–positive JIA, 157 (12.8%) as having enthesitis/spondylitis–related JIA, 38 (3.1%) as having systemic JIA, and 10 (0.8%) as having rheumatoid factor–positive JIA. A total of 12% of patients were unclassifiable using the ILAR criteria, while 63.3% were unclassifiable using the PRINTO criteria (777 with other JIA and 2 with unclassified JIA). In sensitivity analyses, &gt;50% of patients remained unclassifiable using the PRINTO criteria. Compared to the PRINTO criteria, ILAR JIA categories aligned better with clinicobiologic subtypes in 131 patients (χ 2 = 44, P = 0.005, versus χ 2 = 15, P = 0.07 for PRINTO), and ILAR categories aligned better with adult types of arthritis in 389 evaluable patients. Conclusion Currently identified PRINTO disorders can only be used to classify a minority of JIA patients, leaving a large proportion of JIA patients with other disorders requiring further characterization. Current PRINTO JIA classification criteria do not align better with clinicobiologic subtypes or adult forms of arthritis compared with the older ILAR classification system.
PARTICIPANT CHARACTERISTICS AND PATTERNS OF ENGAGEMENT IN MOBILE HEALTH CARDIAC REHABILITATION
Authors: Claire Graves, Antoinette Schoenthaler, Greg Sweeney, Ana Fonceva, Jonathan Whiteson, Barbara J. George, Kevin Phillip Marzo, Elizabeth Rerisi, Lara Kovell, Samrachana Adhikari, John A. Dodson
Journal: Journal of the American College of Cardiology (2022)
A SUPERVISED LEARNING METHOD FOR THE CLASSIFICATION OF ELECTRONIC HEALTH RECORDBASED HEART FAILURE PHENOTYPES
Authors: Nosheen Reza, William Bone, Pankhuri Singhal, Yifan Yang, Anurag Verma, Ashwin Murthy, Srinivas Denduluri, Srinath Adusumalli, Marylyn D. Ritchie, Thomas P. Cappola
Journal: Journal of the American College of Cardiology (2022)
OPTIMAL MEDICAL THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN A MIDDLE-INCOME COUNTRY: A MULTICENTER REGISTRY
Authors: Mariana Gil, Sofia Leal, Juan Carlos Santis, Josue F. Samayoa Ruano, Magda I. Ramos Castro, Elisa M. Anleu De Leon, Oscar F. Castro Alvarado, Paola Overall, Luis A. Rodriguez Cifuentes, Karla Y. Miranda Sandoval, Juan P. Pineda, Kevin O. Flores Andrade, Roberto A. Perez Reyes, Sofia W. Giron Blas
Journal: Journal of the American College of Cardiology (2022)
EVALUATION OF THE OPEN-CLEAN CHRONIC TOTAL OCCLUSION PERCUTANEOUS CORONARY INTERVENTION PERFORATION SCORE IN THE PROGRESS-CTO REGISTRY
Authors: Spyridon Kostantinis, Brynn Okeson, Bahadir Simsek, Judit Karacsonyi, Barry F. Uretsky, Abdul Sheikh, Brian K. Jefferson, Taral N. Patel, Jason R. Wollmuth, Robert F. Riley, M Nicholas Burke, Santiago Garcia, Stewart M. Benton, Rhian E. Davies, James W. Choi, David E. Kandzari, Raj H. Chandwaney, Catalin Toma, Evangelia Vemmou, Ilias Nikolakopoulos, Nidal Abi Rafeh, Omer Goktekin, Ahmed M. ElGuindy, Bavana V. Rangan, Emmanouil S. Brilakis
Journal: Journal of the American College of Cardiology (2022)
Gitelman-Like Syndrome Caused by Pathogenic Variants in mtDNA
Authors: Daan Viering, Karl P. Schlingmann, Marguerite Hureaux, Tom Nijenhuis, Andrew Mallett, Melanie M.Y. Chan, André van Beek, Albertien M. van Eerde, Jean-Marie Coulibaly, Marion Vallet, Stéphane Decramer, Solenne Pelletier, Günter Klaus, Martin Kömhoff, Rolf Beetz, Chirag Patel, Mohan Shenoy, Eric J. Steenbergen, Glenn Anderson, Ernie M.H.F. Bongers, Carsten Bergmann, Daan Panneman, Richard J. Rodenburg, Robert Kleta, Pascal Houillier, Martin Konrad, Rosa Vargas-Poussou, Nine V.A.M. Knoers, Detlef Bockenhauer, Jeroen H.F. de Baaij
Journal: Journal of the American Society of Nephrology (2021)

Gitelman syndrome is the most frequent hereditary salt-losing tubulopathy characterized by hypokalemic alkalosis and hypomagnesemia. Gitelman syndrome is caused by biallelic pathogenic variants in SLC12A3, encoding the Na+-Cl- cotransporter (NCC) expressed in the distal convoluted tubule. Pathogenic variants of CLCNKB, HNF1B, FXYD2, or KCNJ10 may result in the same renal phenotype of Gitelman syndrome, as they can lead to reduced NCC activity. For approximately 10 percent of patients with a Gitelman syndrome phenotype, the genotype is unknown.We identified mitochondrial DNA (mtDNA) variants in three families with Gitelman-like electrolyte abnormalities, then investigated 156 families for variants in MT-TI and MT-TF, which encode the transfer RNAs for phenylalanine and isoleucine. Mitochondrial respiratory chain function was assessed in patient fibroblasts. Mitochondrial dysfunction was induced in NCC-expressing HEK293 cells to assess the effect on thiazide-sensitive 22Na+ transport.Genetic investigations revealed four mtDNA variants in 13 families: m.591C>T (n=7), m.616T>C (n=1), m.643A>G (n=1) (all in MT-TF), and m.4291T>C (n=4, in MT-TI). Variants were near homoplasmic in affected individuals. All variants were classified as pathogenic, except for m.643A>G, which was classified as a variant of uncertain significance. Importantly, affected members of six families with an MT-TF variant additionally suffered from progressive chronic kidney disease. Dysfunction of oxidative phosphorylation complex IV and reduced maximal mitochondrial respiratory capacity were found in patient fibroblasts. In vitro pharmacological inhibition of complex IV, mimicking the effect of the mtDNA variants, inhibited NCC phosphorylation and NCC-mediated sodium uptake.Pathogenic mtDNA variants in MT-TF and MT-TI can cause a Gitelman-like syndrome. Genetic investigation of mtDNA should be considered in patients with unexplained Gitelman syndrome-like tubulopathies.
Natural killer cells: Innate immune system as a part of adaptive immunotherapy in hematological malignancies
Authors: Ivo Demel, Zdenek Koristek, Benjamin Motais, Roman Hajek, Tomas Jelinek
Journal: American Journal of Hematology (2022)

Natural killer (NK) cells are part of a phylogenetically old defense system, which is characterized by its strong cytolytic function against physiologically stressed cells such as tumor cells and virus-infected cells. Their use in the treatment of hematological malignancies may be more advantageous in several ways when compared with the already established T lymphocyte-based immunotherapy. Given the different mechanisms of action, allogeneic NK cell products can be produced in a non-personal based manner without the risk of the formidable graft-versus-host disease. Advanced manufacturing processes are capable of producing NK cells relatively easily in large and clinically sufficient numbers, useable without subsequent manipulations or after genetic modifications, which can solve the lack of specificity and improve clinical efficacy of NK cell products. This review summarizes the basic characteristics of NK cells and provides a quick overview of their sources. Results of clinical trials in hematological malignancies are presented, and strategies on how to improve the clinical outcome of NK cell therapy are discussed.
Achieving Global Pediatric Palliative Care Equity—What We Have Yet to Learn
Authors: Puja J. Umaretiya, Joanne Wolfe
Journal: JAMA Network Open (2022)

Michael J. McNeil, MD; Bella S. Ehrlich, BA; Huiqi Wang, MS; Yuvanesh Vedaraju, MS; Marisol Bustamante, MD; Veronica Dussel, MD, MPH; Paola Friedrich, MD, MPH; Ximena Garcia Quintero, MD; Srinithya R. Gillipelli, BS; Wendy Gomez Garcia, MD; Dylan E. Graetz, MD, MPH; Erica C. Kaye, MD, MPH; Monika L. Metzger, MD; Carla Vittoria Sabato Danon, MS; Meenakshi Devidas, PhD, MBA; Justin N. Baker, MD; Asya Agulnik, MD, MPH; Assessing Doctors' Attitudes on Palliative Treatment (ADAPT) Latin America Study Group; Florencia Moreno; Beatriz Salas; Rosa Moreno; Cinthia Cespedes; Gissela Sanchez; Soad Fuentes; Silvia Rivas; Pascale Gaussant; Clarissa Aguilar; Enrique Lopez; Roberta Ortiz; Diana Cedeño; Angelica Samudio; Jazmin Servin; Cecilia Ugaz Olivares; Fabiana Morosini; Alejandra Chacon; Lilliana Barragan; Ruth María Castro; Juliana Lopera; Miguel Bayona; Diana Lorena Valencia Libreros; Natalia Perdomo; Jeyni Vega; Wendy Rivera; Rosa Vanessa Cabrera; Emmanuel Guerrero; Soledad Jimenez; Libeth Bosh; Doris Calle; Sergio Quintanilla; Sandra Felix; Susana Anaya; Judith Conejo Barrera; Lilliana Gallegos; Martha Valdez; Valentine Jimenez; Susana Juarez; Berenice Aguilar; Adolfo Pineda; Isodoro Romero; Norma Arecil Lopez Facundo; Gelis Ruis Piña; Edgar Francisco Ortiz; Norma Llamas; Rosario Batista
Re: Fabio Turco, Andrew Armstrong, Gerhardt Attard, et al. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022;82:6–11
Authors: Yu Wei, Yao Zhu, Dingwei Ye
Journal: European Urology (2022)
A FIXED VALVE BUT A DAMAGED LEAD
Authors: Syed Rafay Ali Sabzwari, James Mann, Lukasz Patrick Cerbin, Christopher Barrett, John Jason West, Alexis Z. Tumolo, Lohit Garg, Michael Rosenberg, Ryan G. Aleong, Paul D. Varosy, Wendy S. Tzou, Amneet Sandhu, Matthew Michael Zipse
Journal: Journal of the American College of Cardiology (2022)
TRENDS IN PERMANENT PACEMAKER IMPLANTATION IN TRANSCATHETER AORTIC VALVE REPLACEMENT USING THE CUSP OVERLAP TECHNIQUE: INSIGHTS FROM THE EPROMPT REGISTRY
Authors: Giorgio Medranda, Toby Rogers, Brian Case, Syed Ali, Cheng Zhang, John C. Wang, Gaby Weissman, Lowell F. Satler, Itsik Ben-Dor, Ron Waksman
Journal: Journal of the American College of Cardiology (2022)
Abstract P4-05-04: Menopausal breast cancer: Bone mineral density (BMD) and prognostic factors
Journal: Cancer Research (2022)

Abstract Aims: Study the relationship between Bone Mineral Density (BMD) before breast cancer and prognostic factors in menopausal breast cancerMethods: Study 340 menopausal breast cancer, BMD before breast cancer and prognostic factors. The bone mineral density was measured using z score femur of dual energy X-ray absorptiometry (DXA), z score was classified between &amp;gt; 1 - &amp;lt; -1 and &amp;gt; -1. Analyze z score with the prognostic factors (tumor size T1 versus T2-3, nodes positive versus negative, histologic grade I vs II-III, hormonal receptor positive versus negative, HER2 positive versus negative, Ki 67 &amp;gt; 20 versus &amp;lt;20, p53 positive versus negative), tumor subtype (Luminal versus No Luminal), bilateral tumor (synchronous, asynchronous) and recurrences. Results: The mean age of the 340 patients was 61 years. Score femur of dual energy X-ray absorptiometry (DXA) was &amp;gt; 1 - &amp;lt; -1 in 284 (84'41%) and &amp;gt; -1 - -3'8 in 53 (15'58) patients. Tumor size was greater than 2 centimeters in 55 16.17%) patients and in 285 (83.82%) patients up to 2 centimeters. Histological Grade (HG) was I in 196 (57.64%), II in 121/35.58) and III in 23 (6.76%) patients. The. z score femur of dual energy X-ray absorptiometry (DXA) was&amp;gt; 1 - &amp;lt; -1 in 284 (84'41%) patients and&amp;gt; -1 - -3'8 in 53 (15'58) patients. Tumor size was greater than 2 centimeters in 55 (16.17%) patients and in 285 (83.82%) patients up to 2 centimeters. Histological Grade (HG) was I in 196 (57.64%), II in 121/35.58) and III in 23 (6.76%) patients. The tumor subtype was Luminal A in 276 (82.65%), Luminal B HER2- in 64 (18.87%), Luminal B HER2 + in 26 (7.66%), HER2 + in 12 (3.52%). and Triple Negative in 12 (3.53%) patients. Recurrences were in. 14 patients. The z score of dual energy X-ray absorptiometry (DXA) before breast cancer &amp;gt; +1 - &amp;lt; -1 was related (p&amp;lt;0'05) to HG I, T1, Luminal tumor subtypes and HER2+ tumor subtypes. It is not related (p=ns) to positive nodes, hormonal receptors (HR), Ki 67, p53 positive and bilateral synchronous and asynchronous tumor. Conclusion. The z score of dual energy X-ray absorptiometry (DXA) before breast cancer can give us information on the prognostic factors of menopausal breast cancer Citation Format: Menopausal breast cancer: Bone mineral density (BMD) and prognostic factors [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-05-04.
Neoadjuvant Approaches in Hepatocellular Carcinoma: There's No Time Like the Present
Authors: Joseph W. Franses, Andrew X. Zhu
Journal: Clinical Cancer Research (2022)

Abstract Hepatocellular carcinoma (HCC) remains a lethal malignancy and is an increasingly common cause of cancer death worldwide. Curative-intent surgical resection remains the standard of care for eligible patients, yet outcomes remain poor for many patients, with most patients experiencing recurrence in the 5 years after resection. There is currently significant interest in using locoregional and systemic therapies—in both the neoadjuvant and adjuvant settings—to increase the chance of cure. This review article appraises the existing literature and current clinical trial landscape of neoadjuvant therapies in HCC.
Increased 68Ga-FAPI Uptake in Sacral Chordoma
Authors: Xiao Yang, Chunru Mou, Yong Wang, Huipan Liu, Yue Chen
Journal: Clinical Nuclear Medicine (2021)

A 47-year-old woman presented with low back pain for 2 months. Her CT scan showed a soft tissue mass in S3 to S4 vertebral bodies. The patient was subsequently enrolled in our 68Ga-FAPI clinical trial on tumors (ChiCTR2100044131). Increased tracer uptake was noted in the sacrum. Postoperative pathology confirmed the diagnosis of sacral chordoma accordingly.
Lipid mediators are detectable in the nasal epithelium and differ by asthma status in female subjects
Authors: Randi K. Johnson, Jonathan Manke, Monica Campbell, Michael Armstrong, Meher Preethi Boorgula, Gabriela Pinheiro, Cinthia Vila Nova Santana, Rasika A. Mathias, Kathleen C. Barnes, Alvaro Cruz, Nichole Reisdorph, Camila A. Figueiredo
Journal: Journal of Allergy and Clinical Immunology (2022)
META-ANALYSIS COMPARING ASPIRIN VERSUS P2Y12 INHIBITOR FOR SECONDARY PREVENTION IN PATIENTS WITH ESTABLISHED CORONARY ARTERY DISEASE
Authors: Amit Rout, Aakash Garg, Apurv Agarwal, Udaya Tantry, Abigail Chan, Vikas Singh, Paul A. Gurbel
Journal: Journal of the American College of Cardiology (2022)
Solving neurodegeneration: common mechanisms and strategies for new treatments
Authors: Lauren K. Wareham, Shane A. Liddelow, Sally Temple, Larry I. Benowitz, Adriana Di Polo, Cheryl Wellington, Jeffrey L. Goldberg, Zhigang He, Xin Duan, Guojun Bu, Albert A. Davis, Karthik Shekhar, Anna La Torre, David C. Chan, M. Valeria Canto-Soler, John G. Flanagan, Preeti Subramanian, Sharyn Rossi, Thomas Brunner, Diane E. Bovenkamp, David J. Calkins
Journal: Molecular Neurodegeneration (2022)

Across neurodegenerative diseases, common mechanisms may reveal novel therapeutic targets based on neuronal protection, repair, or regeneration, independent of etiology or site of disease pathology. To address these mechanisms and discuss emerging treatments, in April, 2021, Glaucoma Research Foundation, BrightFocus Foundation, and the Melza M. and Frank Theodore Barr Foundation collaborated to bring together key opinion leaders and experts in the field of neurodegenerative disease for a virtual meeting titled "Solving Neurodegeneration". This "think-tank" style meeting focused on uncovering common mechanistic roots of neurodegenerative disease and promising targets for new treatments, catalyzed by the goal of finding new treatments for glaucoma, the world's leading cause of irreversible blindness and the common interest of the three hosting foundations. Glaucoma, which causes vision loss through degeneration of the optic nerve, likely shares early cellular and molecular events with other neurodegenerative diseases of the central nervous system. Here we discuss major areas of mechanistic overlap between neurodegenerative diseases of the central nervous system: neuroinflammation, bioenergetics and metabolism, genetic contributions, and neurovascular interactions. We summarize important discussion points with emphasis on the research areas that are most innovative and promising in the treatment of neurodegeneration yet require further development. The research that is highlighted provides unique opportunities for collaboration that will lead to efforts in preventing neurodegeneration and ultimately vision loss.
Is a location-based resect-and-discard strategy the right approach?
Authors: Ahmir Ahmad, Brian P. Saunders
Journal: Endoscopy (2022)

See also: The location-based resect and discard strategy for diminutive colorectal polyps: a prospective clinical studyEndoscopy 2022; 54(04): 354-363DOI: 10.1055/a-1546-9169
LDHA-MEDIATED ROS SCAVENGING PROMOTES CARDIAC REGENERATION VIA INHIBITING SUCCINYLATION-DEPENDENT UBIQUITINATION OF TXNRD1
Authors: Yanmei Chen, Yijin Chen, Mengsha Li, Guangkai Wu, Yu Liu, Wei Chen, Yili Sun, Haoxiang Huang, Yating Pan, Jianping Bin
Journal: Journal of the American College of Cardiology (2022)
High-Flow Nasal Oxygen for Severe Hypoxemia: Oxygenation Response and Outcome in Patients with COVID-19
Authors: V. Marco Ranieri, Tommaso Tonetti, Paolo Navalesi, Stefano Nava, Massimo Antonelli, Antonio Pesenti, Giacomo Grasselli, Domenico Luca Grieco, Luca Salvatore Menga, Lara Pisani, Annalisa Boscolo, Nicolò Sella, Laura Pasin, Chiara Mega, Giacinto Pizzilli, Alessio Dell’Olio, Roberto Dongilli, Paola Rucci, Arthur S. Slutsky
Journal: American Journal of Respiratory and Critical Care Medicine (2021)

The "Berlin definition" of acute respiratory distress syndrome (ARDS) does not allow inclusion of patients receiving high-flow nasal oxygen (HFNO). However, several articles have proposed that criteria for defining ARDS should be broadened to allow inclusion of patients receiving HFNO.
C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer
Authors: Niklas Klümper, Jonas Saal, Fiamma Berner, Christa Lichtensteiger, Nina Wyss, Annkristin Heine, Franz Georg Bauernfeind, Jörg Ellinger, Peter Brossart, Stefan Diem, Sabine Schmid, Markus Joerger, Martin Frueh, Manuel Ritter, Michael Hölzel, Lukas Flatz, Tobias Bald
Journal: Journal for ImmunoTherapy of Cancer (2022)

Biomarkers for predicting response to anti-programmed death-1 (PD-1) immune checkpoint blockade (ICB) in non-small cell lung cancer (NSCLC) remain in demand. Since anti-tumor immune activation is a process, early dynamic changes of the acute-phase reactant C reactive protein (CRP) may serve as a predictive on-treatment biomarker. In a retrospective (N=105) and prospective (N=108) ICB-treated NSCLC cohort, early CRP kinetics were stratified after the start of immunotherapy until weeks 4, 6, and 12 as follows: an early doubling of baseline CRP followed by a drop below baseline (CRP flare-responder), a drop of at least 30% below baseline without prior flare (CRP responders), or those who remained as CRP non-responders. In our study, we observed characteristic longitudinal changes of serum CRP concentration after the initiation of ICB. In the prospective cohort, N=40 patients were defined as CRP non-responders, N=39 as CRP responders, and N=29 as CRP flare-responders with a median progression-free survival (PFS) of 2.4, 8.1, and 14.3 months, respectively, and overall survival (OS) of 6.6, 18.6, and 32.9 months (both log-rank p&lt;0.001). Of note, CRP flare-responses, characterized by a sharp on-treatment CRP increase in the first weeks after therapy initiation, followed by a decrease of CRP serum level below baseline, predict ICB response as early as 4 weeks after therapy initiation. Of note, early CRP kinetics showed no predictive value for chemoimmunotherapy or when steroids were administered concurrently. On-treatment CRP kinetics had a predictive value for both major histological NSCLC subtypes, adenocarcinoma and squamous cell carcinoma. The results were verified in an independent retrospective cohort of 105 patients. In conclusion, CRP flare predicted anti-PD-1 monotherapy response and survival in two independent cohorts including a total of 213 patients with NSCLC, regardless of histology. Due to its wide clinical availability, early CRP kinetics could become an easily determined, cost-efficient, and non-invasive biomarker to predict response to checkpoint inhibitors in NSCLC within the first month.